Pamicell "Stem Cell Therapy Recovers 2 out of 3 Severe COVID-19 Patients"

[Asia Economy Reporter Hyunseok Yoo] Pharmicell announced on the 27th that its allogeneic mesenchymal stem cell therapy Cellgram-AKI is being used to treat COVID-19, and so far, all three patients who received the treatment have recovered.

A company official stated, "All three patients who received Cellgram-AKI were in a very critical condition, suffering from acute respiratory distress syndrome (ARDS) with persistent hypoxia until just before the treatment, requiring intubation and mechanical ventilation. The first and third patients showed improvement and have maintained a stable condition after just one administration." He added, "The second patient was treated during a rapid worsening of pneumonia but unfortunately did not recover and died from sepsis."

Pharmicell noted that fortunately, due to the government's proactive quarantine measures, the number of severe COVID-19 cases in South Korea has been steadily decreasing. Although the rapid approval of Cellgram-AKI by the Ministry of Food and Drug Safety has not yet allowed treatment for many patients, the company intends to maintain the availability of Cellgram-AKI for long-term response.

In particular, although the number of domestic cases has significantly decreased and severe patients continue to decline, there are still a considerable number of patients in intensive care units using life-support devices such as ventilators. Stem cell therapy is expected to have high therapeutic effects when started during early deterioration. However, even patients who have stayed in the ICU for a long time with severely damaged lung function or multiple organ failure can potentially recover organ functions due to the characteristics of stem cells. Therefore, Pharmicell plans to supply the therapy upon request from the attending physician. Upon such a request, Pharmicell will promptly send and support the necessary documents for approval from the hospital Institutional Review Board (IRB) to ensure rapid provision of the treatment.

Meanwhile, interest in stem cell therapy continues to grow as numerous clinical results and papers reporting successful treatment of COVID-19 patients using stem cells have recently been published in countries such as China, Israel, and the United States.

This content was produced with the assistance of AI translation services.